DIVIE met with Ludovic Mendes, Member of Parliament (LAREM) of Moselle, member of the Information Mission on the Regulation and Impact of Different Uses of Cannabis, and rapporteur on the Welfare Component (CBD). He agreed to answer our questions.
Just over a year ago, the National Assembly launched an Information Mission on the regulation and impact of different cannabis uses, chaired by Mr Robin Réda.
You are a member of this committee and the rapporteur on the welfare component (CBD). Since the launch of this commission, you have heard the various players in the hemp and wellness sector. If you were to explain what Cannabidiol (CBD) is, its properties and potential for farmers, consumers, how would you present it?
Following the various hearings of the Joint Information Mission on the regulation and impact of different cannabis uses, I define CBD as a non-lethal product for humans that could enable some people to find an alternative to pharmaceuticals. The product also has properties to improve sleep and relaxation. It’s the perfect anti-stress! The product is developed on the open market and is highly consumed within the European Union. It is not processed on national territory, as the Interministerial Mission to Combat Drugs and Addictive Conduct prohibits the consumption and production of hemp flower. As France being Europe’s largest producer and the third largest producer of hemp in the world, the development of the market would provide additional resources to farmers via this new market. In practical terms, this means new jobs on our territory. The diversity of finished products, in the form of oil, tea, cream, or dietary supplements demonstrate the ease of use of the product and offers multiple opportunities.
On 19th 2020 November, the European Court of Justice declared that France could not object to the circulation of CBD when it is, I quote, “legally produced in another Member State of the European Union and when it is extracted from the cannabis sativa plant in its entirety.” How is this decision important for the French industry?
It is a revision of the order of 22nd February 1990 which classifies hemp and its resin as narcotics. This text makes no distinction between the varieties of this plant, its different parts, the sex of the plants or their THC content. This decision underlines the preparation of some European countries, which are already ready to market the product, unlike the French sector while our country is renowned for the quality of its know-how. The decision of the European Court of Justice will force France to amend its texts concerning the CBD and thus the exploitation of the hemp flower. The change in the legal paradigm should take place quickly since the amendment does not deal with legislation. I will deliver my progress report mid-January, which deals only with the CBD market, its obstacles, its problems and its future.
When do you think the CBD will finally be fully framed in France?
Personally, I hope that before the end of 2021, a solution will be found to guarantee the quality of products of French origin and at the same time, enable the development of a value-added sector.
The Mission is soon publishing a report calling for a framework for the use of the flower. Can you tell us more about your proposals?
I am clearly in favour of market supervision, for public health reasons and for consideration to be given to the CBD level in products.
In the absence of supervision, there are now many products containing Cannabidiol (CBD) on the French market without any control in terms of traceability and quality.
Last question, can you tell us if you have ever used CBD, and if so, what have been the benefits?
Yes, in different settings, I was able to try CBD, especially through auditions during the Mission. The impact is unique to each person and of course it depends on the use and the purpose. I point out that the product does not have psychotropic and when I consumed it, I noticed a soothing effect.
Thank you, Mr Ludovic Mendes.